08.04.19
NICE recommends monofilament debridement technology for use in acute or chronic wounds
Source: Advertisement feature
Following a comprehensive review, NICE’s Medical Technology Guidance has recommended Debrisoft pad (10x10cm), Debrisoft Lolly and Debrisoft pad (13x20cm), manufactured by Lohmann & Rauscher, as part of the management of acute or chronic wounds in the community.
The NICE committee behind the guidance concluded that using the Debrisoft family would improve speed of debridement, reduce costs and result in a reduction in nursing visits compared to saline and gauze, hydrogel and larvae.
Alison Schofield, tissue viability clinical nurse specialist at North Lincolnshire and Goole NHS Foundation Trust, said: "As a tissue viability specialist nurse supporting clinicians across services in best practice for wound assessment and management, we encourage the maintenance of the optimum wound bed environment and with that preparation is vital. A simple effective intervention for this is use of the Debrisoft pad. Along with the added benefit of the Debrisoft lolly which can access cavity wounds and hard to reach places. In our wound toolkit, Debrisoft is an essential item for chronic wound care aiding mechanical debridement and having evidence based NICE guidance ensures quality care is delivered.”
Guest et al (2015) estimated that 2.2 million wounds are managed by the NHS each year at an annual cost of £5.3m. However, the cost differed according to wound type, with chronic leg ulcers costing as much as £1.94bn to manage each year (Guest et al 2016).
The Debrisoft pad is estimated to be cost saving for complete debridement compared with other debridement methods. When compared with hydrogel, gauze and bagged larvae, cost savings per patient (per complete debridement) are estimated to be £99, £154 and £373 respectively in a community clinic, and £213, £292 and £277 respectively in the home. NICE concluded that there was cost savings to the NHS for the other two variations of the product (Debrisoft Lolly and Debrisoft 13x20cm).
Geraldine Weale, nursing sister, ATU/OPD, Deeside Community Hospital, said that “having used Debrisoft for a number of years now it is an essential product in our ‘Toolbox’ and is very much part of our daily dressing routine. We have used all of the Debrisoft range from the Lolly to the larger size with excellent debridement results especially on areas with hyperkeratosis. Using Debrisoft products made us realise the importance of not only wound cleansing but the peri wound also and certainly brought about a change of practice.”
Rob Lister, consultant dermatologist at Betsi Cadwaladr University Health Board, North Wales said: “I am pleased to hear that the Debrisoft range has retained a positive NICE guidance. I have found Debrisoft to be very useful for removing soft but clingy slough from wounds. It is very quick and convenient to use, and is very well tolerated by patients.”
NICE first recommended the use of Debrisoft pad (10x10cm) in its medical technologies guidance in 2014, and the guidance has been under review since the beginning of 2018.
Simon Mangan, managing director at L&R UK, commented on the re-recommendation: “L&R are honoured to have such a well-respected institute recommending the whole of the Debrisoft family to improve the treatment of acute or chronic wounds. NICE concluded that the likely benefits of using Debrisoft on appropriate wounds are that they will be fully debrided more quickly, with fewer nurse visits needed, compared with other debridement methods, which will result in overall cost saving to the NHS. This is directly aligned with the NHS strategy as well as delivering patient focused care which L&R are delighted to be able to support.”
The Debrisoft range (L&R Medical UK) are sterile and single-use monofilament debridement devices intended for nurses and other healthcare professionals to use on adults and children to remove devitalised tissue, debris, and hyperkeratotic skin around acute or chronic wounds.
For more information on the Debrisoft range click here: https://lohmann-rauscher.co.uk/woundcare/debrisoft
To read the NICE guidance in full click here: https://www.nice.org.uk/guidance/mtg17